Please ensure Javascript is enabled for purposes of website accessibility

Should Novavax Be Worried About Losing IP Rights?

By Taylor Carmichael - May 6, 2021 at 6:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The danger is overstated.

On Wednesday, President Joe Biden announced that his administration supported the waiver of intellectual property (IP) rights for COVID-19 vaccines in negotiations at the World Trade Organization (WTO). Is this a danger for Novavax (NVAX -2.58%) investors? Not really.

One important point is that Biden's announcement is not a law or a verdict in a patent case. It's the announcement of a negotiating position at talks at the WTO. So far, Novavax hasn't lost anything. And WTO agreements require the consensus of all 164 member countries.

Medical professional  injecting a vaccine into a small model of the Earth.

image source: Getty Images

A big stumbling block for the Biden administration is that opening up the door to generic competition won't speed up distribution of COVID-19 vaccines at all. In fact, the problem right now is the slow pace of regulatory approval (in Novavax's case) as well as manufacturing and distribution issues. 

Novavax already has contracts in place to distribute 1.4 billion doses of its vaccine. Over a billion of those doses are going to developing nations at a reduced price.

Over the last year, the company has been rapidly trying to add manufacturing capacity to meet all this demand. In order to make its adjuvant, Matrix-M, Novavax needs saponin, a chemical that comes from Chilean tree bark. And the biotech needs bioreactor bags for the insect cells it uses to create the vaccines.

Ironically it's been the U.S. government blocking the export of key raw materials that has hampered Novavax and the distribution of vaccines to developing nations. If the Biden administration really wants to help, it should loosen those bottlenecks. 

         

Taylor Carmichael owns shares of Novavax. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$36.22 (-2.58%) $0.96

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
397%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.